Cited 0 times in
A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신상준 | - |
dc.contributor.author | 정병하 | - |
dc.contributor.author | 최영득 | - |
dc.date.accessioned | 2024-01-03T00:55:53Z | - |
dc.date.available | 2024-01-03T00:55:53Z | - |
dc.date.issued | 2023-09 | - |
dc.identifier.issn | 2466-0493 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197411 | - |
dc.description.abstract | Purpose: The proper treatment sequence for administering abiraterone acetate plus prednisolone (AAP) and chemotherapeutic agents has not yet been elucidated for metastatic castration-resistant prostate cancer (mCRPC). Hence, this study evaluated the effectiveness and safety of AAP in pre- and post-chemotherapy settings using real-world data. Materials and methods: This prospective, multicenter, open-label, observational study included 506 patients with mCRPC. Patients were classified according to the timing of chemotherapy into pre- and post-chemotherapy groups. The effectiveness and safety of AAP were compared between the groups; the prostate-specific antigen (PSA) response, PSA progression-free survival, and radiologic progression-free survival were assessed; and adverse drug reactions were recorded. Results: Among the included patients, 319 and 187 belonged to the pre- and post-chemotherapy groups, respectively. Risk classification was similar between the two groups. The PSA response was 61.8% in the pre-chemotherapy group and 39.0% in the post-chemotherapy group (p<0.001). The median time to PSA progression (5.00 vs. 2.93 mo, p=0.001) and radiologic progression-free survival (11.84 vs. 9.17 mo, p=0.002) were significantly longer in the pre-chemotherapy group. Chemotherapy status was associated with PSA (hazard ratio [HR] 1.39, 95% confidence interval [CI] 1.09-1.77) and radiologic progression (HR 1.66, 95% CI 1.18-2.33) during AAP treatment. Adverse drug reactions were reported at similar frequencies in both groups. Conclusions: In this postmarketing surveillance, AAP benefited patients with mCRPC, especially in settings before chemotherapy was administered, resulting in a high PSA response and longer PSA and radiologic progression-free survival with tolerable adverse drug reactions. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Urological Association | - |
dc.relation.isPartOf | INVESTIGATIVE AND CLINICAL UROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Drug-Related Side Effects and Adverse Reactions* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Prostate-Specific Antigen | - |
dc.subject.MESH | Prostatic Neoplasms, Castration-Resistant* / drug therapy | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Seung-Hwan Jeong | - |
dc.contributor.googleauthor | Sang Eun Yeon | - |
dc.contributor.googleauthor | Su Youn Kim | - |
dc.contributor.googleauthor | Tae Gyun Kwon | - |
dc.contributor.googleauthor | Seong Soo Jeon | - |
dc.contributor.googleauthor | Young Deuk Choi | - |
dc.contributor.googleauthor | Dongdeuk Kwon | - |
dc.contributor.googleauthor | Byung Ha Chung | - |
dc.contributor.googleauthor | Sung-Hoo Hong | - |
dc.contributor.googleauthor | Byung Hoon Kim | - |
dc.contributor.googleauthor | Hyo Jin Lee | - |
dc.contributor.googleauthor | Sang Joon Shin | - |
dc.contributor.googleauthor | Woo Suk Choi | - |
dc.contributor.googleauthor | Sung Woo Park | - |
dc.contributor.googleauthor | Taek Won Kang | - |
dc.contributor.googleauthor | Seok Joong Yun | - |
dc.contributor.googleauthor | Jin Seon Cho | - |
dc.contributor.googleauthor | See Min Choi | - |
dc.contributor.googleauthor | Na-Ri Lee | - |
dc.contributor.googleauthor | Cheol Kwak | - |
dc.identifier.doi | 10.4111/icu.20230128 | - |
dc.contributor.localId | A02105 | - |
dc.contributor.localId | A03607 | - |
dc.contributor.localId | A04111 | - |
dc.relation.journalcode | J01185 | - |
dc.identifier.eissn | 2466-054X | - |
dc.identifier.pmid | 37668202 | - |
dc.subject.keyword | Abiraterone | - |
dc.subject.keyword | Prostate cancer | - |
dc.subject.keyword | Prostate-specific antigen | - |
dc.subject.keyword | Real-world data | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | 신상준 | - |
dc.contributor.affiliatedAuthor | 정병하 | - |
dc.contributor.affiliatedAuthor | 최영득 | - |
dc.citation.volume | 64 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 466 | - |
dc.citation.endPage | 473 | - |
dc.identifier.bibliographicCitation | INVESTIGATIVE AND CLINICAL UROLOGY, Vol.64(5) : 466-473, 2023-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.